Press Releases from MetrioPharm AG (2 total)
MetrioPharm Achieves 50% of Target Patients Randomized in MP1032 Phase II Clinic …
Zurich, August 14, 2018. MetrioPharm AG, a pharmaceutical biotech company developing drugs for chronic inflammatory diseases, today announced that more than 50% of patients with moderate-to-severe psoriasis (PASI entry score 10-20) have been randomized in the company’s ongoing Phase II clinical trial.
The Phase II study is being conducted in Germany and Poland as a multicenter, randomized, double-blind, placebo-controlled, twice-daily oral trial over 12 weeks. Psoriasis patients aged 18 to 70…
MetrioPharm announces first patients dosed in a clinical phase IIa trial for MP1 …
Zurich, June 07, 2016. MetrioPharm AG announces the first dosing of patients in the phase IIa clinical trial MP1032-CT02 on May 24, 2016. To date, five patients were successfully enrolled. MP1032 can inhibit inflammation by reducing the concentration of small proteins (cytokines) that are involved in the inflammation process in diseases such as chronic plaque psoriasis. MP1032 also has the potential to reduce susceptibility to bacterial and viral infections. MP1032…
